An NCI-designated Comprehensive Cancer Center

Jasmine M. Zain, M.D.

Hematologist; Oncologist
Clinical Expertise
  • T Cell Lymphoma
  • Hematology/Oncology
Research Focus
  • Lymphoma
Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation; Director, T cell Lymphoma Program; Tim Nesvig Lymphoma Research Fellow

Clinical Teams

  • Cutaneous Lymphoma Program
Jasmine Zain M.D., is an associate clinical professor in the Department of Hematology & Hematopoietic Cell Transplantation. Additionally, she is the Tim Nesvig Lymphoma Research Fellow, as well as director of the T cell Lymphoma Program at the Toni Stephenson Lymphoma Center at City of Hope.
Dr. Zain obtained her medical degree from Fatima Jinnah Medical College for Women in Lahore Pakistan. She went on to complete an internship and residency at North Shore Hospital of Forest Hills in Forest Hills, NY, followed by a hematology/oncology fellowship at New York University Medical Center. She then took a position at The Brooklyn Hospital as an attending physician, followed by an appointment as assistant professor in the Department of Medicine at the University of Connecticut. In 2002,
Dr. Zain first joined City of Hope where she specialized in the treatment of patients with cutaneous T-cell lymphoma, allogeneic stem cell transplantation, and early phase clinical trials in hematologic malignancies. She left City of Hope to assume a leadership position as director of the bone marrow transplant program at New York University Langone Medical Center, before joining the faculty at Columbia University in 2012.
Triple-board certified in hematology, oncology and internal medicine, Dr. Zain is an active member of several professional associations, and has published more than 78 peer-reviewed publications, abstracts and book chapters. She served as an Associate Editor for two journals in her field - Clinical Lymphoma and Myeloma, and Clinical Cancer Research - and has been invited to speak both nationally and internationally.
Dr. Zain is a superb clinician, a productive and creative clinical researcher, and an outstanding and experienced teacher.


City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

Sirutin and Pan- Class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma. Amengual JE, Clark-Garvey S, Kalac M, Scotto L, Marchi E, Neylon E, Johannet P, Wei Y, Zain J, O'Connor OA. Blood. 2013 Sep 19; 122(12):2104-13. Epub 2013 Aug 2.
An unusual extra nodal presentation of non-Hodgkin lymphoma. Phillips AA, Zain J.Clin Adv Hematol Oncol. 2012 Sep; 10(9):623-5.
Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. Knobler R, Duvic M, Querfeld C, Straus D, Horwitz S, Zain J, Foss F, Kuzel T, Campbell K, Geskin L. Photodermatol Photoimmunol Photomed. 2012 Oct;28(5):250-7. doi: 10.1111/j.1600-0781.2012.00689.x.
Novel therapeutic agents for cutaneous T-Cell lymphoma. Jain S, Zain J, O'Connor O.J Hematol Oncol. 2012 May 17; 5:24.
Role of histone deacetylase inhibitors in the treatment of lymphomas and multiple myeloma. Zain J. Hematol Oncol Clin North Am. 2012 Jun;26(3):671-704, ix. Epub 2012 Mar 28.
Novel therapeutic agents for cutaneous T-Cell lymphoma. Jain S, Zain J, O'Connor O. J Hematol Oncol. 2012 May 17;5:24
Safety and efficacy of Brentuximab Vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Gopal AK, Ramchandren R, O'Connor OA, Berryman RB, Advani RH, Chen R, Smith SE, Cooper M, Rothe A, Matous JV, Grove LE, Zain J. Blood. 2012 Jul 19;120(3):560-8. Epub 2012 Apr 17.
A phase 2 study of Vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517.Kirschbaum MH, Goldman BH, Zain JM, Cook JR, Rimsza LM, Forman SJ, Fisher RI: Leuk Lymphoma. 2011 Sep 19.
Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. Zain J, Palmer JM, Delioukina M, Thomas S, Tsai NC, Nademanee A, Popplewell L, Gaal K, Senitzer D, Kogut N, O'Donnell M, Forman SJ:  Leuk Lymphoma. 2011 Aug;52(8):1463-73.
Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. Jain S, Diefenbach C, Zain J, O'Connor OA:  Core Evid. 2011; 6:43-57.
A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia.Kirschbaum MH, Synold T, Stein AS, Tuscano J, Zain JM, Popplewell L, Karanes C, O'Donnell MR, Pulone B, Rincon A, Wright J, Frankel P, Forman SJ, Newman EM : Leukemia. 2011 Oct;25(10):1543-7.
Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Delioukina M, Zain J, Palmer JM, Tsai N, Thomas S, Forman S. Bone Marrow Transplant. 2011 Feb 28.
This is an abbreviated listing. Request CV for full publications listing.
In The News
An Expert's Voice
Rare Disease Day | City of Hope

Finding better treatments for devastating rare diseases

red and white blood cells illustration stock - large hi res

City of Hope investigators present breakthrough research at 60th American Society of Hematology meeting

Jasmine Zain

Cutaneous T cell lymphoma Q&A: Treatment, misdiagnosis, and advances in research